Literature DB >> 3049815

A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1).

D C Altieri1, T S Edgington.   

Abstract

CD11b/CD18 (Mac-1) is a member of the leukocyte integrin family, a group of receptors that have been implicated in various effector functions and cellular collaboration in the immune response. It has been shown previously that CD11b/CD18 on cells of monocyte and myeloid lineage appears to undergo rapid activation and acquire new functional receptor specificities after exposure to selected agonists such as adenosine diphosphate (ADP). We now show that ADP induces a reconformation of the CD11b/CD18 receptor with exposure of new epitopes characteristics of this activated state. By direct binding studies, flow cytometry, and immunoprecipitation experiments, it has been found that the mAb 7E3 reacts with CD11b/CD18 only after ADP-stimulation of the cell suspension. The activated state of CD11b/CD18 induced by ADP and recognized by 7E3 can also be recapitulated by agonists inducing transients in cytosolic Ca2+ such as the chemoattractant FMLP. Moreover, this process of receptor activation does not involve quantitative mobilization of the subcellular storage pool of CD11b/CD18 to the plasma membrane. Because 7E3 also recognizes a qualitative, ADP-mediated activated state of the platelet adhesion receptor GP IIb/IIIa, it is suggested that transients in cytosolic Ca2+ might represent early secondary events for a general pathway of rapid activation of integrin receptors and, as such, represent important signals for cellular interactions in the immune response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049815

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.

Authors:  M I Furman; A L Frelinger III; A D Michelson
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

Review 2.  The role of CD15-(Le(X))-related carbohydrates in neutrophil adhesion.

Authors:  M A Kerr; S C Stocks
Journal:  Histochem J       Date:  1992-11

3.  Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

Authors:  C Weber; T A Springer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 4.  The role of neutrophils in vascular injury: a summary of signal transduction mechanisms in cell/cell interactions.

Authors:  G Weissmann
Journal:  Springer Semin Immunopathol       Date:  1989

Review 5.  New perspectives on basic mechanisms in lung disease. 2. Neutrophil traffic in the lungs: role of haemodynamics, cell adhesion, and deformability.

Authors:  W MacNee; C Selby
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

6.  Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor.

Authors:  J R Gamble; M J Elliott; E Jaipargas; A F Lopez; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Lymphocyte adhesion to Candida albicans.

Authors:  Christopher B Forsyth; Herbert L Mathews
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

8.  A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits.

Authors:  C Rogers; E R Edelman; D I Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 9.  Adhesion molecules and their role in cancer metastasis.

Authors:  R M Lafrenie; M R Buchanan; F W Orr
Journal:  Cell Biophys       Date:  1993 Aug-Dec

Review 10.  Abciximab. An updated review of its use in ischaemic heart disease.

Authors:  R H Foster; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.